marketcaparena
Search

    ZYME

    Zymeworks Inc.

    Company overview

    Market capitalization
    $1.92B
    Employees
    243
    Latest publication
    2026-09-29
    About Zymeworks Inc.

    Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease. It has strategic partnerships and collaborations with Jazz Pharmaceuticals plc; Bristol- Myers Squibb company; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Merck Sharp & Dohme Research GmbH; and Janssen Biotech, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ1 20242024-03-31 · USD
    Total Revenue4,590,000USD2,408,000USD2,500,000USD27,614,000USD48,726,000USD27,110,000USD31,031,000USD10,030,000USD
    Cost Of Revenue27,435,000USD0USD—0USD0USD3,305,000USD-26,741,000USD32,742,000USD
    Gross Profit-22,845,000USD2,408,000USD—27,614,000USD48,726,000USD27,110,000USD31,031,000USD10,030,000USD
    General And Administrative Expenses19,335,000USD15,069,000USD—14,146,000USD14,951,000USD———
    Total Operating Expenses19,335,000USD49,526,000USD46,667,000USD49,724,000USD49,400,000USD52,723,000USD53,248,000USD47,832,000USD
    Operating Income-42,180,000USD-47,118,000USD—-22,110,000USD-674,000USD-25,613,000USD-22,217,000USD-37,802,000USD
    Total Other Income Expense Net-3,112,000USD765,000USD—3,844,000USD2,805,000USD3,473,000USD4,426,000USD6,224,000USD
    Income Before Tax-45,292,000USD-46,353,000USD—-18,266,000USD2,131,000USD-22,140,000USD-17,791,000USD-31,578,000USD
    Income Tax Expense-273,000USD-2,191,000USD—1,336,000USD-186,000USD496,000USD5,715,000USD75,000USD
    Net Income-45,019,000USD-44,162,000USD-41,209,000USD-19,602,000USD2,317,000USD-22,636,000USD-23,506,000USD-31,653,000USD
    Research Development—34,457,000USD2,515,000USD35,578,000USD34,449,000USD35,738,000USD37,063,000USD32,042,000USD
    Selling General Administrative—15,069,000USD—14,146,000USD14,951,000USD17,000,000USD16,200,000USD1,200,000USD
    Net Income Applicable To Common Shares—-44,222,000USD—-19,770,000USD2,316,000USD———
    Interest Income—————3,424,000USD4,082,000USD5,920,000USD
    Interest Expense—————0USD——
    Net Interest Income—————3,424,000USD4,082,000USD5,920,000USD
    Tax Provision—————496,000USD5,715,000USD75,000USD
    Net Income From Continuing Ops—————-22,636,000USD-23,506,000USD-31,653,000USD
    Ebit—————-25,628,000USD-22,232,000USD-23,212,000USD
    Ebitda—————-22,323,000USD-18,543,000USD-20,900,000USD
    Depreciation And Amortization—————3,305,000USD3,689,000USD2,312,000USD
    Reconciled Depreciation—————3,305,000USD3,689,000USD2,312,000USD
    Unclassified Operating Expenses———————14,590,000USD
    SourceDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosurePreliminaryDisclosureDeterministicFinalDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20182018-12-31 · USDFY 20172017-12-31 · USDFY 20162016-12-31 · USDFY 20152015-12-31 · USD
    Total Revenue105,965,000USD412,482,000USD26,680,000USD38,951,000USD53,019,000USD51,762,000USD11,009,000USD9,660,000USD
    Cost Of Revenue0USD208,703,000USD199,539,000USD170,896,000USD56,926,000USD41,144,000USD35,551,000USD24,403,000USD
    Gross Profit105,965,000USD412,482,000USD26,680,000USD38,951,000USD53,019,000USD10,618,000USD-24,542,000USD-14,743,000USD
    Research Development137,000,000USD208,596,000USD199,752,000USD168,534,000USD56,684,000USD41,749,000USD36,816,000USD24,654,000USD
    Selling General Administrative61,514,000USD73,358,000USD42,561,000USD57,885,000USD29,457,000USD18,550,000USD12,554,000USD5,217,000USD
    General And Administrative Expenses61,514,000USD———————
    Total Operating Expenses198,514,000USD281,954,000USD242,313,000USD226,419,000USD86,146,000USD59,224,000USD48,105,000USD29,620,000USD
    Operating Income-92,549,000USD130,528,000USD-215,633,000USD-187,468,000USD-33,127,000USD-8,998,000USD-37,864,000USD-19,960,000USD
    Total Other Income Expense Net12,795,000USD4,706,000USD3,274,000USD7,345,000USD-1,258,000USD-964,000USD-1,020,000USD824,000USD
    Income Before Tax-79,754,000USD135,234,000USD-212,359,000USD-180,123,000USD-34,385,000USD-9,962,000USD-38,884,000USD-19,136,000USD
    Income Tax Expense1,376,000USD10,893,000USD-516,000USD429,000USD2,171,000USD444,000USD-5,075,000USD34,000USD
    Net Income-81,130,000USD124,341,000USD-211,843,000USD-180,552,000USD-36,556,000USD-10,406,000USD-33,809,000USD-19,170,000USD
    Net Income Applicable To Common Shares-81,326,000USD124,341,000USD-211,843,000USD-180,552,000USD-36,556,000USD-10,926,000USD-33,809,000USD-19,170,000USD
    Interest Income—3,596,000USD2,505,414USD5,697,000USD2,638,000USD743,000USD308,000USD824,000USD
    Interest Expense—3,596,000USD12,857,000USD17,624,000USD166,000USD1,140,000USD950,000USD18,000USD
    Net Interest Income—3,596,000USD2,505,414USD5,697,000USD2,472,000USD-149,000USD-642,000USD—
    Tax Provision—10,893,000USD-516,000USD429,000USD2,171,000USD444,000USD-5,075,000USD34,000USD
    Net Income From Continuing Ops—124,341,000USD-211,843,000USD-180,552,000USD-36,556,000USD-10,406,000USD-33,809,000USD-19,170,000USD
    Ebit—130,528,000USD-215,633,000USD-187,468,000USD-33,127,000USD-8,822,000USD-37,285,000USD-19,118,000USD
    Ebitda—142,532,000USD-206,050,000USD-177,189,000USD-29,497,000USD-6,083,000USD-36,260,000USD-18,624,000USD
    Depreciation And Amortization—12,004,000USD9,583,000USD10,279,000USD3,630,000USD2,739,000USD1,025,000USD494,000USD
    Reconciled Depreciation—12,004,000USD12,218,517USD10,279,000USD3,630,000USD2,739,000USD——
    Non Operating Income Net Other——1,309,000USD7,345,000USD-1,092,000USD———
    Selling And Marketing Expenses———41,000USD————
    Unclassified Operating Expenses—————-1,075,000USD-1,265,000USD—
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets396,964,000USD478,215,000USD346,527,000USD397,269,000USD408,385,000USD425,522,000USD463,091,000USD487,152,000USD
    Cash And Equivalents179,413,000USD244,282,000USD41,157,000USD64,834,000USD98,253,000USD———
    Total Current Assets298,388,000USD385,680,000USD248,767,000USD291,712,000USD296,130,000USD306,467,000USD300,451,000USD343,769,000USD
    Other Current Assets21,759,000USD16,279,000USD15,332,000USD10,427,000USD12,120,000USD16,586,000USD18,860,000USD22,865,000USD
    Total Liabilities316,595,000USD314,626,000USD78,026,000USD77,205,000USD73,879,000USD———
    Total Current Liabilities47,243,000USD35,649,000USD42,318,000USD42,043,000USD38,502,000USD65,103,000USD88,294,000USD83,909,000USD
    Other Non Current Liabilities278,000USD278,000USD278,000USD278,000USD828,000USD———
    Total Stockholder Equity80,369,000USD163,589,000USD268,501,000USD320,064,000USD334,506,000USD324,967,000USD338,768,000USD366,978,000USD
    Total Equity Including Noncontrolling Interest80,369,000USD163,589,000USD268,501,000USD320,064,000USD334,506,000USD———
    Deferred Revenue16,436,000USD2,078,000USD2,418,000USD3,197,000USD3,811,000USD———
    Deferred Revenue Non Current0USD14,606,000USD14,606,000USD14,607,000USD14,607,000USD———
    Net Receivables5,930,000USD4,674,000USD4,638,000USD29,352,000USD2,631,000USD24,594,000USD55,815,000USD23,704,000USD
    Property Plant Equipment Net27,150,000USD28,870,000USD31,226,000USD32,467,000USD32,574,000USD33,408,000USD34,316,000USD35,688,000USD
    Goodwill12,016,000USD12,016,000USD12,016,000USD12,016,000USD12,016,000USD———
    Accounts Payable27,458,000USD30,226,000USD4,403,000USD1,305,000USD32,000USD5,223,000USD3,903,000USD3,423,000USD
    Short Term Debt3,304,000USD3,279,000USD3,471,000USD3,400,000USD3,586,000USD3,258,000USD2,740,000USD2,943,000USD
    Common Stock1,133,959,000USD1,128,553,000USD1,105,176,000USD1,092,929,000USD1,074,079,000USD1,030,128,000USD1,023,806,000USD1,022,515,000USD
    Retained Earnings-1,171,238,000USD-1,073,834,000USD-953,160,000USD-886,472,000USD-850,654,000USD-852,971,000USD-830,335,000USD-797,834,000USD
    Accumulated Other Comprehensive Income-6,694,000USD-6,565,000USD-6,079,000USD-6,050,000USD-6,340,000USD-6,406,000USD-6,952,000USD-5,999,000USD
    Intangible Assets—————3,362,000USD4,576,000USD6,578,000USD
    Total Liab—————100,555,000USD124,323,000USD120,174,000USD
    Other Current Liab—————32,995,000USD54,685,000USD48,284,000USD
    Capital Stock—————1,030,128,000USD1,023,806,000USD1,022,515,000USD
    Good Will—————12,016,000USD12,016,000USD12,016,000USD
    Cash—————76,204,000USD66,103,000USD122,356,000USD
    Cash And Short Term Investments—————265,287,000USD225,776,000USD297,200,000USD
    Current Deferred Revenue—————23,495,000USD25,588,000USD27,188,000USD
    Net Debt—————-57,744,000USD-47,597,000USD-102,106,000USD
    Short Long Term Debt Total—————18,460,000USD18,506,000USD20,250,000USD
    Long Term Investments—————56,324,000USD98,428,000USD77,667,000USD
    Short Term Investments—————189,083,000USD159,673,000USD174,844,000USD
    Property Plant Equipment Gross—————33,408,000USD52,146,000USD35,688,000USD
    Common Stock Shares Outstanding—————75,226,387shares75,878,738shares76,157,101shares
    Non Current Assets Total—————119,055,000USD162,640,000USD143,383,000USD
    Non Current Liabilities Total—————35,452,000USD36,029,000USD36,265,000USD
    Non Current Liabilities Other—————828,000USD895,000USD896,000USD
    Non Currrent Assets Other—————9,096,000USD8,919,000USD7,228,000USD
    Net Working Capital—————241,364,000USD212,157,000USD259,860,000USD
    Unclassified Non Current Assets—————4,849,000USD4,385,000USD4,205,999USD
    Unclassified Non Current Liabilities—————34,624,000USD35,134,000USD35,369,000USD
    Unclassified Equity—————-875,912,000USD-871,557,000USD-874,219,000USD
    Unclassified Current Liabilities——————1,378,000USD2,071,000USD
    Other Assets———————1USD
    SourceDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets346,527,000USD463,091,000USD580,880,000USD648,725,000USD389,132,000USD538,376,000USD368,205,000USD244,363,000USD
    Cash And Equivalents41,157,000USD———————
    Total Current Assets248,767,000USD300,451,000USD412,926,000USD544,706,000USD288,220,000USD455,076,000USD311,830,000USD204,369,000USD
    Other Current Assets15,332,000USD18,860,000USD19,122,000USD19,074,000USD19,998,000USD13,429,000USD10,741,000USD3,847,000USD
    Total Liabilities78,026,000USD———————
    Total Current Liabilities42,318,000USD88,294,000USD55,763,000USD95,625,000USD71,853,000USD85,666,000USD82,552,000USD29,986,000USD
    Other Non Current Liabilities278,000USD———————
    Total Stockholder Equity268,501,000USD338,768,000USD464,806,000USD492,956,000USD249,094,000USD409,922,000USD245,681,000USD-145,272,000USD
    Total Equity Including Noncontrolling Interest268,501,000USD———————
    Deferred Revenue2,418,000USD———————
    Deferred Revenue Non Current14,606,000USD———————
    Net Receivables4,638,000USD55,815,000USD19,477,000USD33,400,000USD15,614,000USD15,293,000USD2,185,000USD358,000USD
    Property Plant Equipment Net31,226,000USD34,316,000USD37,543,000USD47,650,000USD49,770,000USD17,614,000USD16,500,000USD6,484,000USD
    Goodwill12,016,000USD———————
    Accounts Payable4,403,000USD3,903,000USD6,212,000USD7,863,000USD5,174,000USD6,244,000USD5,349,000USD2,599,000USD
    Short Term Debt3,471,000USD2,740,000USD4,261,000USD3,322,000USD1,310,000USD2,710,000USD1,282,000USD15,000USD
    Common Stock1,105,176,000USD1,023,806,000USD1,006,572,000USD906,764,000USD741,147,000USD724,219,000USD450,210,000USD320,074,000USD
    Retained Earnings-953,160,000USD-830,335,000USD-677,437,000USD-558,763,000USD-683,104,000USD-471,261,000USD-290,709,000USD-145,272,000USD
    Accumulated Other Comprehensive Income-6,079,000USD-6,952,000USD-6,603,000USD-6,659,000USD-6,659,000USD-6,659,000USD-6,659,000USD-6,659,000USD
    Intangible Assets—4,576,000USD25,284,000USD26,383,000USD21,466,000USD22,931,000USD23,685,000USD20,010,000USD
    Total Liab—124,323,000USD116,074,000USD155,769,000USD140,038,000USD128,454,000USD122,524,000USD63,873,000USD
    Other Current Liab—54,685,000USD39,780,000USD65,003,000USD65,369,000USD76,712,000USD75,921,000USD23,558,000USD
    Capital Stock—1,023,806,000USD1,006,572,000USD906,764,000USD741,147,000USD724,219,000USD450,210,000USD320,074,000USD
    Good Will—12,016,000USD12,016,000USD12,016,000USD12,016,000USD12,016,000USD12,016,000USD12,016,000USD
    Other Assets—-162,477,360,000USD—34,712,000USD34,402,000USD65,812,000USD21,802,000USD19,994,000USD
    Cash—66,103,000USD157,557,000USD400,912,000USD201,867,000USD242,036,000USD128,451,000USD42,205,000USD
    Cash And Short Term Investments—225,776,000USD374,327,000USD492,232,000USD252,608,000USD426,354,000USD298,904,000USD200,164,000USD
    Current Deferred Revenue—25,588,000USD3,699,000USD2,353,000USD57,593,000USD37,411,000USD30,342,000USD3,530,000USD
    Net Debt—-47,597,000USD-130,835,000USD-372,799,000USD-169,534,000USD-233,392,000USD-121,524,000USD-42,148,000USD
    Short Long Term Debt Total—18,506,000USD26,722,000USD28,113,000USD32,333,000USD8,644,000USD6,927,000USD57,000USD
    Long Term Investments—98,428,000USD82,148,000USD886,000USD886,000USD25,921,000USD——
    Short Term Investments—159,673,000USD216,770,000USD91,320,000USD50,741,000USD184,318,000USD170,453,000USD157,959,000USD
    Property Plant Equipment Gross—52,146,000USD58,199,000USD60,949,000USD63,831,000USD12,185,000USD23,732,000USD—
    Common Stock Shares Outstanding—75,878,738shares68,863,010shares65,249,184shares52,131,596shares50,382,497shares38,022,014shares29,089,896shares
    Non Current Assets Total—162,640,000USD167,954,000USD104,019,000USD100,912,000USD83,300,000USD56,375,000USD39,994,000USD
    Non Current Liabilities Total—36,029,000USD60,311,000USD60,144,000USD68,185,000USD42,788,000USD39,972,000USD33,887,000USD
    Non Current Liabilities Other—895,000USD1,609,000USD2,977,000USD33,671,000USD8,669,000USD978,000USD904,000USD
    Non Currrent Assets Other—8,919,000USD7,566,000USD15,739,000USD13,704,000USD3,095,000USD2,956,000USD1,400,000USD
    Net Working Capital—212,157,000USD357,163,000USD449,081,000USD275,872,252USD369,410,000USD229,278,000USD174,383,000USD
    Unclassified Non Current Assets—4,385,000USD3,397,000USD-33,367,000USD-31,332,000USD-64,089,000USD-20,584,000USD-19,910,000USD
    Unclassified Current Liabilities—1,378,000USD1,811,000USD17,084,000USD-57,593,000USD-37,411,000USD-30,342,000USD—
    Unclassified Non Current Liabilities—35,134,000USD58,702,000USD4,176,000USD-37,262,000USD-36,976,000USD-13,611,000USD-19,637,000USD
    Unclassified Equity—-871,557,000USD-864,298,000USD-755,150,000USD-543,437,000USD-560,596,000USD-357,371,000USD-633,489,000USD
    Inventory——1USD———1USD1USD
    Deferred Long Term Liab———17,638,000USD34,514,000USD34,119,000USD18,278,000USD18,661,000USD
    Other Liab———35,353,000USD37,262,000USD36,976,000USD34,327,000USD33,959,000USD
    Net Tangible Assets———472,185,000USD215,612,000USD374,975,000USD227,608,000USD166,860,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Depreciation1,139,000USD1,691,000USD2,584,000USD3,214,000USD3,305,000USD3,689,000USD2,663,000USD2,529,000USD
    Stock Based Compensation6,935,000USD-3,410,727USD6,911,000USD5,871,000USD6,402,000USD5,021,000USD4,664,000USD4,555,000USD
    Change To Account Receivables-36,000USD24,417,575USD-26,721,000USD21,989,000USD31,219,000USD-31,630,000USD7,880,000USD-1,141,000USD
    Change To Liabilities-7,750,000USD———————
    Change In Working Capital-9,528,000USD18,559,239USD-20,684,000USD-154,000USD9,964,000USD-26,946,000USD16,723,000USD-10,069,000USD
    Operating Cash Flow-45,718,000USD———————
    Capital Expenditures-216,000USD-569,895USD-410,000USD-884,000USD-338,000USD-314,000USD-1,002,000USD-1,096,000USD
    Net Investments70,175,000USD———————
    Investing Cash Flow69,959,000USD———————
    Common Stock Issuance8,717,000USD———————
    Net Common Stock Issuance-76,151,000USD———————
    Unclassified Financing Cash Flow246,220,000USD6,623,057USD-1,416,196,000USD1,433,288USD————
    Financing Cash Flow178,786,000USD———————
    Effect Of Forex Changes On Cash98,000USD———————
    Change In Cash203,125,000USD-23,677,000USD-33,419,000USD22,049,000USD10,101,000USD-56,253,000USD51,393,000USD-43,851,000USD
    End Cash Flow244,282,000USD———————
    Net Income—-41,209,000USD-19,602,000USD2,317,000USD-22,636,000USD-23,506,000USD-29,850,000USD-37,686,000USD
    Other Non Cash Items—12,968,171USD-451,000USD710,000USD-32,000USD-893,000USD136,000USD15,872,000USD
    Total Cash From Operating Activities—-9,982,255USD-31,412,000USD12,073,000USD-3,407,000USD-41,508,000USD-5,868,000USD-24,993,000USD
    Free Cash Flow—-10,552,150USD-31,822,000USD11,189,000USD-3,745,000USD-41,822,000USD-6,870,000USD-26,089,000USD
    Investments—6,088,000USD368,000USD8,745,000USD12,182,000USD-6,214,000USD72,257,000USD-19,971,000USD
    Total Cashflows From Investing Activities—5,100,004USD368,000USD8,745,000USD12,182,000USD-6,214,000USD72,257,000USD-19,971,000USD
    Total Cash From Financing Activities—-18,783,794USD-2,452,000USD1,319,000USD1,316,000USD-8,644,000USD-14,988,000USD1,051,000USD
    Sale Purchase Of Stock—-25,319,886USD1,425,000,000USD—0USD-9,427,000USD-20,624,000USD—
    Issuance Of Capital Stock—0USD———0USD0USD—
    Begin Period Cash Flow—64,834,000USD98,253,000USD76,204,000USD66,103,000USD122,356,000USD70,963,000USD114,814,000USD
    End Period Cash Flow—41,157,000USD64,834,000USD98,253,000USD76,204,000USD66,103,000USD122,356,000USD70,963,000USD
    Other Cashflows From Investing Activities—-47,413,748,996USD160,528,370,000USD-370,000USD-322,000USD-51,725USD-103,000USD-503,000USD
    Other Cashflows From Financing Activities—-86,965USD-11,256,000USD-114,288USD1,316,000USD785,000USD5,639,000USD1,054,000USD
    Unclassified Operating Cash Flow—1,419,062USD———1,127,000USD——
    Unclassified Investing Cash Flow—47,413,330,895USD-160,527,960,000USD1,254,000USD——1,105,000USD1,599,000USD
    Net Borrowings—————-2,000USD-3,000USD—
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Stock Based Compensation28,034,000USD17,792,000USD8,102,000USD4,015,000USD10,756,000USD29,116,000USD48,996,000USD13,441,000USD
    Deferred Income Tax945,000USD———————
    Change To Account Receivables51,200,000USD-36,359,000USD13,922,000USD-17,509,000USD-266,000USD-13,107,000USD-1,828,000USD-119,000USD
    Change To Liabilities-23,648,000USD——26,479,000USD16,477,000USD7,618,000USD21,273,000USD3,824,000USD
    Change In Working Capital34,016,000USD-30,953,000USD-25,545,000USD4,015,000USD393,000USD-10,148,000USD6,440,000USD39,925,000USD
    Operating Cash Flow-33,005,000USD———————
    Capital Expenditures-1,521,000USD-3,066,000USD-4,077,000USD-13,125,000USD-13,285,000USD-6,265,000USD-13,878,000USD-3,420,000USD
    Net Investments29,015,000USD———————
    Unclassified Investing Cash Flow-831,000USD4,141,000USD5,680,000USD-27,599,000USD—1,955,000USD7,556,000USD105,626,000USD
    Investing Cash Flow26,663,000USD———————
    Common Stock Issuance16,904,000USD———————
    Net Common Stock Issuance-41,695,000USD———————
    Unclassified Financing Cash Flow6,232,000USD—70,269,000USD106,131,000USD-2,070,000USD300,910,000USD188,231,000USD—
    Financing Cash Flow-18,559,000USD———————
    Effect Of Forex Changes On Cash-45,000USD———————
    Change In Cash-24,946,000USD-91,454,000USD-243,355,000USD199,045,000USD-40,169,000USD113,585,000USD86,246,000USD6,259,000USD
    End Cash Flow41,157,000USD———————
    Net Income—-122,695,000USD-118,674,000USD124,341,000USD-211,843,000USD-180,552,000USD-145,437,000USD-36,556,000USD
    Depreciation—11,193,000USD17,305,000USD12,004,000USD9,583,000USD10,279,000USD7,331,000USD3,630,000USD
    Other Non Cash Items—13,928,000USD1,266,000USD-2,206,000USD-387,000USD-364,000USD1,543,000USD3,754,000USD
    Total Cash From Operating Activities—-110,044,000USD-118,303,000USD144,109,000USD-192,451,000USD-151,403,000USD-81,853,000USD24,177,000USD
    Free Cash Flow—-113,110,000USD-122,380,000USD130,984,000USD-205,736,000USD-157,668,000USD-95,731,000USD20,757,000USD
    Investments—38,756,000USD-207,253,000USD-53,849,000USD157,881,000USD-37,175,000USD-11,714,000USD-105,626,000USD
    Total Cashflows From Investing Activities—38,756,000USD-207,253,000USD-53,849,000USD144,596,000USD-43,440,000USD-25,592,000USD-109,046,000USD
    Net Borrowings—-14,000USD-21,000USD-14,000USD-17,000USD-41,000USD-16,000USD-11,000USD
    Total Cash From Financing Activities—-20,452,000USD81,847,000USD108,582,000USD8,011,000USD308,978,000USD193,661,000USD91,431,000USD
    Sale Purchase Of Stock—-30,051,000USD820,000,000USD1,403,000USD2,070,000USD1,111,000USD598,000USD91,434,000USD
    Issuance Of Capital Stock—0USD76,095,000USD107,534,000USD107,720,000USD300,910,000USD188,231,000USD90,752,000USD
    Begin Period Cash Flow—157,557,000USD400,912,000USD201,867,000USD242,036,000USD128,451,000USD42,205,000USD35,946,000USD
    End Period Cash Flow—66,103,000USD157,557,000USD400,912,000USD201,867,000USD242,036,000USD128,451,000USD42,205,000USD
    Other Cashflows From Investing Activities—-1,075,000USD-1,603,000USD40,724,000USD-881,000USD-1,955,000USD-7,556,000USD-105,626,000USD
    Other Cashflows From Financing Activities—9,613,000USD5,773,000USD1,062,000USD8,028,000USD8,109,000USD5,446,000USD690,000USD
    Change To Inventory——1,602,000USD———-9,774,000USD-111,000USD
    Dividends Paid——-814,174,000USD——-1,111,000USD-598,000USD—
    Unclassified Operating Cash Flow———1,940,000USD————
    Cash And Cash Equivalents Changes————-39,844,000USD114,135,000USD86,216,000USD6,562,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ3 20252025-09-30 · USDQ2 20252025-06-30 · USD
    Stock Based Compensation19,184,000USD12,273,000USD
    Change To Account Receivables26,487,000USD53,208,000USD
    Change To Liabilities-24,983,000USD-28,324,000USD
    Change In Working Capital14,021,000USD33,219,000USD
    Operating Cash Flow-22,746,000USD8,666,000USD
    Capital Expenditures-940,000USD-530,000USD
    Net Investments22,927,000USD22,149,000USD
    Unclassified Investing Cash Flow-692,000USD-692,000USD
    Investing Cash Flow21,295,000USD20,927,000USD
    Common Stock Issuance10,079,000USD2,156,000USD
    Net Common Stock Issuance-16,216,000USD—
    Unclassified Financing Cash Flow6,320,000USD479,000USD
    Financing Cash Flow183,000USD2,635,000USD
    Effect Of Forex Changes On Cash-1,000USD-78,000USD
    Change In Cash-1,269,000USD32,150,000USD
    End Cash Flow64,834,000USD98,253,000USD
    SourceDisclosureDeterministicFinalDisclosureDeterministicFinal

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q2 2026Quarterly · 2026-06-30ProductDrug Supply1,709,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductDrug Supply For Ongoing Studies791,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductMilestone Revenue0USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductOption Exercise Fee0USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductRecognition Of Deferred Revenue0USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductResearch Support Payments And Other Service291,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductRoyalty1,799,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31ProductDrug Supply117,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31ProductDrug Supply For Ongoing Studies345,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31ProductMilestone Revenue0USDDisclosure
    Q1 2026Quarterly · 2026-03-31ProductResearch Support Payments And Other Service392,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31ProductRoyalty1,554,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30ProductDeferred Revenue0USDDisclosure
    Q3 2025Quarterly · 2025-09-30ProductDrug Supply71,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30ProductDrug Supply For Ongoing Studies970,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30ProductMilestone Revenue25,000,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30ProductOption Exercise Fee0USDDisclosure
    Q3 2025Quarterly · 2025-09-30ProductResearch Period Extension Fee250,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30ProductResearch Support Payments And Other Service352,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30ProductRoyalty971,000USDDisclosure
    Q2 2025Quarterly · 2025-06-30ProductDeferred Revenue18,334,000USDDisclosure
    Q2 2025Quarterly · 2025-06-30ProductDrug Supply7,000USDDisclosure
    Q2 2025Quarterly · 2025-06-30ProductDrug Supply For Ongoing Studies1,841,000USDDisclosure
    Q2 2025Quarterly · 2025-06-30ProductMilestone Revenue20,000,000USDDisclosure
    Q2 2025Quarterly · 2025-06-30ProductOption Exercise Fee7,500,000USDDisclosure
    Q2 2025Quarterly · 2025-06-30ProductResearch Support Payments And Other Service475,000USDDisclosure
    Q2 2025Quarterly · 2025-06-30ProductRoyalty569,000USDDisclosure
    FY 2024Yearly · 2024-12-31ProductCredit For Program Amendments0USDDisclosure
    FY 2024Yearly · 2024-12-31ProductDrug Supply18,473,000USDDisclosure
    FY 2024Yearly · 2024-12-31ProductDrug Supply For Ongoing Studies19,228,000USDDisclosure
    FY 2024Yearly · 2024-12-31ProductMilestone Revenue35,500,000USDDisclosure
    FY 2024Yearly · 2024-12-31ProductOption Exercise Fee0USDDisclosure
    FY 2024Yearly · 2024-12-31ProductRecognition Of Deferred Revenue0USDDisclosure
    FY 2024Yearly · 2024-12-31ProductResearch Period Extension Fee0USDDisclosure
    FY 2024Yearly · 2024-12-31ProductResearch Support Payments And Other Service3,003,000USDDisclosure
    FY 2024Yearly · 2024-12-31ProductRoyalty100,000USDDisclosure
    Q1 2024Quarterly · 2024-03-31ProductDrug Supply1,578,000USD0001937653-25-000027
    Q1 2024Quarterly · 2024-03-31ProductDrug Supply For Ongoing Studies6,218,000USD0001937653-25-000027
    Q1 2024Quarterly · 2024-03-31ProductMilestone Revenue0USD0001937653-25-000027
    Q1 2024Quarterly · 2024-03-31ProductResearch Support Payments And Other Service2,234,000USD0001937653-25-000027
    Q1 2024Quarterly · 2024-03-31ProductRoyalty0USD0001937653-25-000027
    Q3 2023Quarterly · 2023-09-30ProductCredit For Program Amendments0USD0001937653-24-000050
    Q3 2023Quarterly · 2023-09-30ProductDrug Supply6,023,000USD0001937653-24-000050
    Q3 2023Quarterly · 2023-09-30ProductDrug Supply For Ongoing Studies7,559,000USD0001937653-24-000050
    Q3 2023Quarterly · 2023-09-30ProductMilestone Revenue0USD0001937653-24-000050
    Q3 2023Quarterly · 2023-09-30ProductResearch Support Payments And Other Service2,924,000USD0001937653-24-000050
    FY 2022Yearly · 2022-12-31ProductCredit For Program Amendments0USD0001937653-25-000014
    FY 2022Yearly · 2022-12-31ProductDrug Supply194,000USD0001937653-25-000014
    FY 2022Yearly · 2022-12-31ProductDrug Supply For Ongoing Studies3,610,000USD0001937653-25-000014
    FY 2022Yearly · 2022-12-31ProductLicensing And Technology Transfer Fee375,000,000USD0001937653-25-000014
    FY 2022Yearly · 2022-12-31ProductLicensing Fee5,000,000USD0001937653-25-000014
    FY 2022Yearly · 2022-12-31ProductMilestone Revenue0USD0001937653-25-000014
    FY 2022Yearly · 2022-12-31ProductResearch Support Payments And Other Service28,678,000USD0001937653-25-000014
    FY 2022Yearly · 2022-12-31ProductRoyalty0USD0001937653-25-000014
    Q3 2022Quarterly · 2022-09-30ProductCredit For Program Amendments0USD0001937653-23-000037
    Q3 2022Quarterly · 2022-09-30ProductDrug Supply0USD0001937653-23-000037
    Q3 2022Quarterly · 2022-09-30ProductResearch Support Payments And Other Service2,631,000USD0001937653-23-000037
    Q2 2022Quarterly · 2022-06-30ProductCredit For Program Amendments0USD0001937653-23-000028
    Q2 2022Quarterly · 2022-06-30ProductDrug Supply0USD0001937653-23-000028
    Q2 2022Quarterly · 2022-06-30ProductLicense5,000,000USD0001937653-23-000028
    Q2 2022Quarterly · 2022-06-30ProductResearch Support Payments And Other Service442,000USD0001937653-23-000028
    FY 2021Yearly · 2021-12-31ProductCredit For Program Amendments0USD0001937653-24-000019
    FY 2021Yearly · 2021-12-31ProductDrug Supply0USD0001937653-24-000019
    FY 2021Yearly · 2021-12-31ProductDrug Supply For Ongoing Studies0USD0001937653-24-000019
    FY 2021Yearly · 2021-12-31ProductLicensing And Technology Transfer Fee0USD0001937653-24-000019
    FY 2021Yearly · 2021-12-31ProductLicensing Fee0USD0001937653-24-000019
    FY 2021Yearly · 2021-12-31ProductPartner Revenue5,000,000USD0001937653-24-000019
    FY 2021Yearly · 2021-12-31ProductPerformance Milestone16,000,000USD0001937653-24-000019
    FY 2021Yearly · 2021-12-31ProductResearch Support Payments And Other Service5,680,000USD0001937653-24-000019
    FY 2020Yearly · 2020-12-31ProductLicensing And Technology Transfer Fee0USD0001937653-23-000011
    FY 2020Yearly · 2020-12-31ProductLicensing Fee0USD0001937653-23-000011
    FY 2020Yearly · 2020-12-31ProductPartner Revenue4,000,000USD0001937653-23-000011
    FY 2020Yearly · 2020-12-31ProductPerformance Milestone15,000,000USD0001937653-23-000011
    FY 2020Yearly · 2020-12-31ProductResearch Support Payments And Other Service7,951,000USD0001937653-23-000011
    FY 2020Yearly · 2020-12-31ProductUpfront Fee12,000,000USD0001937653-23-000011

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.